Literature DB >> 24715741

Drug monographs: afatinib and obinutuzumab.

Benjamin G Mancheril1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Boulevard #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 24715741      PMCID： PMC3971107          DOI： 10.1310/hpj4903-237

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  12 in total

1.  Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

Authors:  Timothy A Yap; Laura Vidal; Jan Adam; Peter Stephens; James Spicer; Heather Shaw; Jooern Ang; Graham Temple; Susan Bell; Mehdi Shahidi; Martina Uttenreuther-Fischer; Peter Stopfer; Andrew Futreal; Hilary Calvert; Johann S de Bono; Ruth Plummer
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

Authors:  Laurie H Sehn; Sarit E Assouline; Douglas A Stewart; Joy Mangel; Randy D Gascoyne; Gregg Fine; Susan Frances-Lasserre; David J Carlile; Michael Crump
Journal:  Blood       Date:  2012-03-20       Impact factor: 22.113

3.  Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.

Authors:  Peter Stopfer; Kristell Marzin; Hans Narjes; Dietmar Gansser; Mehdi Shahidi; Martina Uttereuther-Fischer; Thomas Ebner
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-27       Impact factor: 3.333

4.  Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

Authors:  Gilles A Salles; Franck Morschhauser; Philippe Solal-Céligny; Catherine Thieblemont; Thierry Lamy; Hervé Tilly; Emmanuel Gyan; Guiyuan Lei; Michael Wenger; Elisabeth Wassner-Fritsch; Guillaume Cartron
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

5.  Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

Authors:  Franck Andre Morschhauser; Guillaume Cartron; Catherine Thieblemont; Philippe Solal-Céligny; Corinne Haioun; Reda Bouabdallah; Pierre Feugier; Krimo Bouabdallah; Elina Asikanius; Guiyuan Lei; Michael Wenger; Elisabeth Wassner-Fritsch; Gilles Andre Salles
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

6.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

7.  Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Authors:  Michinori Ogura; Kensei Tobinai; Kiyohiko Hatake; Toshiki Uchida; Tatsuya Suzuki; Yukio Kobayashi; Masakazu Mori; Yasuhito Terui; Masahiro Yokoyama; Tomomitsu Hotta
Journal:  Cancer Sci       Date:  2012-11-12       Impact factor: 6.716

8.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Authors:  Nobuyuki Katakami; Shinji Atagi; Koichi Goto; Toyoaki Hida; Takeshi Horai; Akira Inoue; Yukito Ichinose; Kunihiko Koboyashi; Koji Takeda; Katsuyuki Kiura; Kazuto Nishio; Yoko Seki; Ryuichi Ebisawa; Mehdi Shahidi; Nobuyuki Yamamoto
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

10.  A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.

Authors:  Michael S Gordon; David S Mendelson; Mitchell Gross; Martina Uttenreuther-Fischer; Mahmoud Ould-Kaci; Yihua Zhao; Peter Stopfer; David B Agus
Journal:  Invest New Drugs       Date:  2012-12-15       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.